Press Releases
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung...
Nivolumab is the first PD-1 immune checkpoint inhibitor to receive a positive opinion from the CHMP in advanced non-small cell lung cancer. ...
Press Releases
Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based Hepatitis C Regimen
Breakthrough Designation for daclatasvir and sofosbuvir combination is supported by the recently presented ALLY-1 trial in patients with advanced cirrhosis or recurrent hepatitis C (HCV)...
Press Releases
Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Raise. Rise.™ to Honor Those Affected by Cancer...
• Ready. Raise. Rise. encourages everyone touched by cancer to create a personalized, virtual flag in honor of a loved one and help raise money...
Press Releases
Lilly and Sanford-Burnham Announce Collaboration to Investigate Immunological Therapies
INDIANAPOLIS, May 14, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover...
Press Releases
Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrate the Promise of its Broad Immuno-Oncology Portfolio...
Pivotal Phase III studies (CheckMate -057 & -017) in both advanced non-squamous and squamous non-small cell lung cancer in which treatment with Opdivo demonstrated superior...
Press Releases
Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding Debt Securities;...
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today that, pursuant to its previously announced cash tender offer for up to $400 million aggregate principal amount...
Press Releases
Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amount of its Outstanding Debt Securities
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for up to $500 million aggregate principal...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.